Summary: In a post-hoc analysis pooling three phase 3 randomised trials of Chinese adults with type 2 diabetes and hypercholesterolemia, tafolecimab 450 mg every four weeks lowered LDL-C by an estimated 64.02% more than placebo at week 12 (95% CI -68.08% to -59.96%, P<0.0001), with significant reductions in triglycerides, non-HDL-C, apolipoprotein B and lipoprotein(a) and a generally similar adverse-event rate. These are 12-week lipid surrogate outcomes in a non-prespecified subgroup, not cardiovascular endpoints.
PICO Summary
| Element | Detail |
|---|---|
| Population | Chinese adults with type 2 diabetes and hypercholesterolemia, identified as a subgroup within pooled data from three phase 3 randomised, placebo-controlled trials; post-hoc analysis; China. |
| Intervention | Tafolecimab (a PCSK9 monoclonal antibody) 450 mg subcutaneously every four weeks, assessed over 12 weeks. |
| Comparison | Placebo, administered on the matching every-four-week schedule within the same pooled trials. |
| Outcome | Primary endpoint, percentage change in LDL-C from baseline to week 12: estimated treatment difference -64.02% (95% CI -68.08% to -59.96%, P<0.0001). Significantly higher proportions reached LDL-C below 1.8 mmol/L and the composite of a 50% or greater reduction plus LDL-C below 1.4 mmol/L (both P<0.0001). Triglycerides, non-HDL-C, apolipoprotein B and lipoprotein(a) were all significantly reduced versus placebo (all P<0.001). Adverse-event incidence was generally similar between groups. Absolute risk reduction and number needed to treat were not reported, and no cardiovascular outcomes were assessed. |
Tafolecimab in T2D + hypercholesterolemia
Post-hoc pooled phase 3 RCT · type 2 diabetes · 12 weeks
Tafolecimab 450 mg every 4 weeks cut LDL-C by about 64% more than placebo at 12 weeks in this diabetic subgroup, with similar tolerability. Surrogate lipid endpoints only; post-hoc and not cardiovascular.
Expert Commentary
The verdict is that tafolecimab produced a large and statistically robust LDL-C reduction in this diabetic, hypercholesterolemic subgroup, with a 64% placebo-adjusted fall that is consistent with the established potency of PCSK9 monoclonal antibodies and is therefore biologically plausible rather than implausibly strong. Secondary lipid fractions moved in the expected direction, and short-term tolerability appeared comparable to placebo. The principal limitation, which should temper enthusiasm, is that this was a post-hoc analysis of a non-prespecified subgroup pooled across three trials, so the findings are hypothesis-generating for patients with diabetes specifically and were not powered to confirm benefit in this group; the 12-week window also captures only surrogate lipid endpoints, with no cardiovascular outcome, durability, or hard-event data. Industry involvement is relevant, as the manufacturer employed several co-authors, and any open-label elements within the pooled trials would further warrant caution. Can I use this with my patients? Not yet as a diabetes-specific recommendation; tafolecimab is reasonable to consider for a Chinese adult who needs further LDL-C lowering on maximally tolerated statin therapy, but its diabetes-subgroup value here remains supportive rather than confirmatory. I would like to see a prespecified, adequately powered trial reporting cardiovascular outcomes and absolute risk measures before this analysis changes practice for diabetic patients.
References
Qi L, Shen H, Chai M, Chen B, He Y, Shi X, et al. Efficacy and safety of tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials. Cardiovasc Diabetol. 2025;24(1):264. doi:10.1186/s12933-025-02816-3